Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $21.00.
A number of research firms recently commented on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective on the stock.
Check Out Our Latest Report on Artiva Biotherapeutics
Institutional Trading of Artiva Biotherapeutics
Artiva Biotherapeutics Stock Performance
Shares of NASDAQ ARTV opened at $5.56 on Friday. The business has a 50-day simple moving average of $10.02. Artiva Biotherapeutics has a twelve month low of $5.54 and a twelve month high of $17.31.
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Research analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Featured Articles
- Five stocks we like better than Artiva Biotherapeutics
- What is a Dividend King?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What does consumer price index measure?
- What Does the Future Hold for Eli Lilly?
- Investing in Commodities: What Are They? How to Invest in Them
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.